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Summary
Objective: Hyaluronic acid (HA) and corticosteroids are both widely used for intra-articular treatment of knee osteoarthritis (OA). We examined
the effect of both drugs in intra-articular treatment for hip OA.
Methods: One hundred and one patients with hip OA were included in a prospective double blind study, using a randomized controlled trial
with a three-armed parallel-group design. Three ultrasound-guided, intra-articular injections were given at 14 days interval. The primary out-
come measure was ‘pain on walking’, registered on a visual analogue scale (VAS). Evaluation was performed at baseline and after 14, 28 and
90 days. The study adhered to the Consolidated Standards of Reporting Trials. All analyses were based on intention-to-treat analyses, and
used ‘mixed-procedures’ with the baseline-observation as covariate.
Results: There were no signiﬁcant interactions with respect to Treatment! Time for any of the analyzed outcome measures. There was a sig-
niﬁcant treatment effect for ‘pain on walking’ (PZ 0.044) due to a signiﬁcant improvement following corticosteroid compared to saline with an
effect-size of 0.6 (95% conﬁdence interval: 0.1e1.1, PZ 0.021). By contrast, HA compared to saline had an effect size of 0.4 (0.1 to 0.9;
PZ 0.13). The peak-effect was obtained after 2 weeks. There was no difference between the treatment groups at endpoint. No signiﬁcant side
effects of the injections were observed.
Conclusions: Patients treated with corticosteroids experienced signiﬁcant improvement during the 3 months of intervention, with an effect size
indicating a moderate clinical effect. Although a similar signiﬁcant result following treatment with HA could not be shown, the effect size in-
dicated a small clinical improvement. A higher number of patients in future HA studies would serve to clarify this point.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyThere has been no indication of any change in the age-
standardized incidence rate of OA over the last four decad-
es1e3. In spite of this, the socioeconomic costs of OA have
increased by 80% in the last 10 years4. Pharmacological in-
terventions are of interest in this context, both as basic
agents of relief and for ﬂares of pain in more acute situa-
tions. They may also have the effect of postponing surgical
interventions, by improving the patient’s perceived quality of
life5.
Nonetheless, the non-operative therapeutic armamentar-
ium recommended for reducing pain and maintaining mobil-
ity in the hip is still very limited with regard to OA6. Some
supplementary therapies recommended for knee OA may,
however, also be considered for use in hip OA.
One of these, hyaluronic acid (HA), is well established
for intra-articular treatment of OA of the knee and is
included in the guidelines for treatment of OA with this local-
ization7. Some controversy exists over the beneﬁt of the
treatments8e10. In one large controlled study, saline has
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OA11.
Similarly, corticosteroid injections are very commonly pre-
scribed in knee OA, even though the results of clinical trials
with these compounds are varied12,13. The relationship be-
tween HA and corticosteroid and their comparability with re-
gard to effect in knee OA still need to be clariﬁed14,15.
Injection therapy for OA of the hip has not been exten-
sively used, presumably due to the fact that access to the
joint is fairly difﬁcult16. Until now, only casuistic evidence
pointing to an effect of HA in the hip has been presen-
ted17e20. The use of corticosteroid injections in hip OA
has been advocated16, and this pain relief has been sup-
ported by controlled studies21,22. Corticosteroid treatment,
however, remains controversial due to a rather short-lived
effect and some reports of adverse events following the
injections21,23.
The former reluctance to injection therapy in the hip may
partly be overcome by the use of ultrasound24 and as a re-
sult, injections are now being used more extensively18,25,26.
The ultrasound method also allows a precise demonstration
of the correct placement of the injections into the hip joint27.
The aim of this study was to compare in a randomized,
controlled, double blind design, and in accordance with
the ‘Consolidated Standards of Reporting Trials’ (CON-
SORT)28 the effect of injections with HA, corticosteroid, or
isotonic saline into hip joints with OA.3
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DESIGN
Prospective double blind study, using a randomized con-
trolled trial with a three-armed parallel-group design.
INTERVENTION
Patients were randomized to (1) one injection with 1 mL
(40 mg Depo-medrol) methylprednisolone corticosteroid
followed by two sham injections, (2) three injections of
2 mL HA (Hyalgan), or (3) three intra-articular injections
of 2 mL saline water. In all cases, including the sham injec-
tions, 1 mL of 1% lidocaine was added to the syringe. The
three intra-articular injections were given at 14 days inter-
val. The primary endpoint status was carried out after 3
months without any interim analyses.
No bed rest was required after the injection. A low level of
physical activity, however, was recommended for the rest of
the day.
BLINDING
The primary investigator placed the needle, aspirated any
joint ﬂuid from the hip joint and ascertained the correct
placement of the needle with the aid of a small injection
of air as previously described27. During these administra-
tions the investigator was blinded from the ultrasound
screen and an assistant performed the actual injection us-
ing a masked syringe. The assistant did not otherwise par-
ticipate in the treatment or follow-up of the patients.
PATIENT MATERIAL
General practitioners and specialists in rheumatology
were asked to refer patients with hip OA. One hundred
and eighty-ﬁve consecutive patients with hip OA referred
to the Department of Rheumatology for the study were eval-
uated in terms of their suitability for participation. Demo-
graphics and clinical characteristics of the patients
included are given in Table I.
Inclusion criteria were hip OA as deﬁned by the ACR cri-
teria29, radiographic changes of hip OA30, age above 18
years, stable medication for at least 3 weeks before inclu-
sion, and written informed consent.
Exclusion criteria were radiographic signs of osteonecro-
sis of the hip, pain demanding morphine or incompatibilitywith long-term observation, pain-free at randomization, par-
ticipation in other medical trials, previous intra-articular injec-
tion in the hip joint within the last 3 months, defects or other
skin changes in the injection area with resultant increased
risk of infection, inﬂammatory or neurological diseases,
poultry allergy, anticoagulation treatment, pregnancy, lan-
guage or intellectual problems, or suspected potential non-
compliance with protocol. Radiograms taken within 6
months prior to the study were accepted.
Patients were asked to continue their usual analgesic
consumption throughout the study. If the pain demanded
change in therapy, the patient was secondarily excluded.
OUTCOME MEASURES
The primary outcome measure was ‘pain on walking’ reg-
istered on a 100 mm visual analogue scale (VAS).
Secondary outcome measures were ‘pain at rest’ on
a VAS, Lequesne score, the Western Ontario and McMas-
ter Universities (WOMAC) total osteoarthritis index, and ‘pa-
tient global assessment’ on a VAS.
PATIENT MATERIAL
A ﬂow diagram of the study is shown in Fig. 1. In the
study period, 185 patients were referred to the department
for this study. Of these, 81 patients were not included in
the study: 25 patients did not want to participate after
information on the study, 12 were pain free, 12 had too
much pain to participate and were mostly referred for
surgery, 9 had signiﬁcant medical diseases, 7 had normal
radiograms, and 16 were excluded for other reasons
(participation in other medical trials, treatment with
anticoagulants, and skin defects). One hundred and four
patients were allocated to trial intervention through a six-
envelope (2! 3 treatments) block randomization. Three
patients subsequently withdrew their consent and were
not treated. Thus the study included a total of 101 patients
receiving their allocated intervention. One patient was in-
cluded with a radiogram showing OA, KellgreneLawrence
score II. However, a new radiogram was run after the sec-
ond injection since the patient reported the onset of leg
shortening after the ﬁrst radiogram. The second radiogram
showed osteonecrosis of the hip and the patient was sub-
sequently excluded. This patient was included in all calcu-
lations in his group.Table I
Baseline characteristics of participants by randomization group. No significant differences between groups were observed
HA
(nZ 33)
Saline
(nZ 36)
Corticosteroid
(nZ 32)
Total
(nZ 101)
Age (years)
[range]
65G 14
[33e88]
64G 11
[32e80]
69G 9
[28e81]
66G 12
[28e88]
Females (%) 61 61 72 64
Pain on walking (mm VAS) 49.2G 24.8 42.4G 19.7 44.0G 19.7 45.1G 21.7
Pain at rest (mm VAS) 25.4G 19.9 29.4G 21.3 20.4G 15.2 25.2G 19.3
Lequesne index (score: 1e24) 10.0G 4.0 9.5G 3.8 8.6G 3.1 9.4G 3.7
WOMAC-total (score: 0e96) 38.7G 14.8 41.2G 14.6 37.3G 15.4 39.2G 14.9
Patient global evaluation (mm VAS) 51.1G 22.2 49.0G 20.2 40.1G 20.2 46.9G 20.8
Kellgren grade IeII (%) 50 65 54 57
Kellgren grade IIIeIV (%) 50 35 46 43
No intra-articular effusion (%) 88 72 78 79
Intra-articular effusion (%) 12 28 22 21
Values are meanG SD.
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CLINICAL EVALUATION
At baseline and each time during follow-up (14, 28 and 90
days), the following measurements were obtained: pain (on
walking and at rest), the ‘patient global assessment’ using
100 mm VAS, Lequesne score31 and WOMAC32. ‘The
OARSI Standing Committee for Clinical Trials Response
Criteria’ were applied and calculated on the basis of the var-
ious VAS values33.
ULTRASOUND EXAMINATION
An Acuson, Sequoia Mountainview, CA, USA was used
for the procedure. The examination of the hip joint was per-
formed with a linear transducer with a center frequency of
14 MHz. The scan was performed with the patient in supine
position and the leg in neutral position.
INJECTION
Non-touch technique was applied. With the patient in su-
pine position and after triple skin disinfection, a needle
(gauge 21, 0.8! 80 mm) was inserted anteriorly 8e10 cm
under the inguinal ligament towards the anterior/inferior
capsule below the femoral head with free hand technique
(Fig. 2). Guided by ultrasound, the needle was traced
from 1 cm below the skin surface all the way to the joint.
Joint ﬂuid was aspirated if present. Thereafter, a small
amount, 0.3e0.5 mL of air was injected into the joint in orderto conﬁrm correct needle placement27. The ultrasound pic-
tures of both the aspiration and the injection of air were re-
corded as evidence of the placement.
ETHICS
The study protocol was approved by the local ethical
committee (KF 02-013/00), and all patients signed informed
consent before entering the study.
STATISTICAL METHODS
Owing to the relative invasiveness of the investigated
treatments, the effect size (ES) was chosen to demonstrate
a ‘‘moderate to large’’ clinical effect.
Thirty patients per group were required to complete the 3-
month study period, which corresponds to a statistically sig-
niﬁcant change (two-tailed, aZ 5%) and an ES34,35 of more
than 0.7 with a power (1 b) of 80%36. The study aimed at
enrolling 36 patients per group, allowing a drop-out rate of
10%. The SAS statistical package (version 8; SAS insti-
tute Inc., Cary, NC, USA) was used for all statistical analy-
ses. The primary analyses were based on intention-to-treat
(ITT) and involved all the patients who received treatment at
baseline using the last-observation carried forward tech-
nique. These patients are subsequently referred to as the
ITT population. When considering the longitudinal part of
the randomized trials, a linear approach was used for re-
peated measurements using the model proposed by PJ
Diggle37, which may be ﬁtted in SAS using the procedurePatient screened
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Fig. 1. Flow diagram of the study population according to the CONSORT statement. Drop-outs were for HA: at 14 days, 1 patient (pt); 28 days,
1 pt.; 90 days, 2 pt. Drop-outs for saline were: 28 days, 1 pt.; 90 days, 2 pt.; and for corticosteroid: 28 days, 2 pt.; 90 days, 4 pt.
166 E. Qvistgaard et al.: Intra-articular treatment of hip osteoarthritis‘PROC MIXED’ based on maximum likelihood estimates of
the parameters. The factor [Subject] was considered as
a random effects factor. The assessment of the treatment
and time effects was of interest in testing for a possible in-
teraction and both treatment and time were considered as
systematic factors e using the baseline value as covariate
to reduce the random variation38 and increase power39.
To report the overall treatment effect following the 3-month
time course, the average ES was calculated for each of the
reported outcome measures; clinically, ESZ 0.2 is consid-
ered small, ESZ 0.5 is moderate, and ESO 0.8 is large35,
with standardized mean differences (SMD) analyzed as rec-
ommended by the Cochrane Collaboration40, making the
results more applicable to general practice. All analyses
were based on the above-mentioned random subject (inter-
cept) model, as several measurements were available on
the same patient41. Unless stated otherwise, all results
are presented explicitly by treatment group as mean (95%
conﬁdence interval, CI), as recommended in the CONSORT
statement42.
Results
STUDY ADHERENCE
The secondary drop-out rate was similar in the three
study groups and 87% of the patients were evaluable at
3-month follow-up (Fig. 1).
The demographics of the patients are presented in Table I;
there were no signiﬁcant differences between the three
treatment groups at baseline.
The primary outcome measure of this study, ‘pain on
walking’, showed no signiﬁcant interaction with respect to
Treatment! Time (PZ 0.14), indicating that there was no
difference between the treatment patterns during the 3
months of treatment [presented in Fig. 3(a)]. Despite that
fact, there was a signiﬁcant treatment effect across all
time-points (PZ 0.044), due to a signiﬁcant improvement
following corticosteroid compared to saline, SMDSteroidZ
0.6 (95% CI: 0.1e1.1, PZ 0.021) whereas HA compared
to saline was SMDHAZ 0.4 (0.1 to 0.9; PZ 0.13). The dif-
ference between placebo (saline) and corticosteroid was
signiﬁcant at 14 and 28 days but vanished after 3 months
(P14 daysZ 0.006; P28 daysZ 0.006; P3 monthsZ 0.58). With
Fig. 2. The injection procedure. Note the antero-lateral approach,
which was used in all cases in the present study after triple skin dis-
infection and by applying non-touch technique.regard to HA vs placebo, the difference was most substan-
tial at 14 and 28 days but vanished after 3 months
(P14 daysZ 0.069; P28 daysZ 0.14; P3 monthsZ 0.57). There
were no signiﬁcant differences between HA and corticoste-
roid at any time-point (PO 0.21). The mean within-group
difference in mm VAS (D‘Pain on walking’) for HA after
14, 28 and 90 days was 10 (95% CI: 18 to 2); 11
(19 to 3) and 11 (19 to 3), respectively. For cortico-
steroid it was 12 (20 to 4); 15 (23 to 7) and 9
(16 to 1), respectively. By contrast, there were no signif-
icant changes for saline: 2 (5 to 9); 1 (8 to 7) and 5
(13 to 2), at any time-point.
Secondary outcome ‘Pain at rest’, showed no signiﬁcant
interaction in relation to Treatment! Time (PZ 0.43). Nor
was there any effect of the treatment when evaluating
data across all time-points [PZ 0.30; data are presented
in Fig. 3(b); SMDSteroidZ 0.4 (0.1 to 0.9, PZ 0.13);
SMDHAZ 0.1 (0.3 to 0.6; PZ 0.56)].
Similar results were obtained regarding the Lequesne in-
dex [Treatment! Time (PZ 0.58); treatment effect across
all time-points (PZ 0.44); SMDSteroidZ 0.3 (0.2 to 0.8;
PZ 0.22); SMDHAZ 0.2 (0.3 to 0.7; PZ 0.47)]
[Fig. 4(a)] and WOMAC index [Treatment! Time
(PZ 0.29); treatment effect (PZ 0.14); SMDSteroidZ 0.5
(0.0 to 1.0; PZ 0.059); SMDHAZ 0.3 (0.2 to 0.7;
PZ 0.28)] [Fig. 4(b)].
Finally, the effects following 3 months of therapy were
evaluated using the ‘patient global assessment’ VAS
(Fig. 5). These data showed no interaction with respect to
Treatment! Time (PZ 0.073), and no indication of
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Fig. 3. Values are meanG SE following 3 months of intervention in
101 patients with hip OA treated with injections of hyaluronic acid
(HA, nZ 33), corticosteroid (nZ 32), or placebo (saline, nZ 36).
(a) For the primary outcome ‘Pain on walking’. (b) For the outcome
‘Pain at rest’.
167Osteoarthritis and Cartilage Vol. 14, No. 2treatment effect overall (PZ 0.29); SMDSteroidZ 0.3 (0.1
to 0.8; PZ 0.17); SMDHAZ0.0 (0.5 to 0.5; PZ 0.97).
To explore whether there was any hidden, additional
information, we applied two subgroup analyses on the pri-
mary outcome measure to test for potential interactions
with the degree of OA [Fig. 6(a)], and to ascertain to what
extent effusion interfered with any treatment effect
[Fig. 6(b)]. There was no signiﬁcant interaction with the
dichotomized Kellgren grading ([IeII]/[IIIeIV]) when the
change (D) in ‘Pain on walking’ was analyzed: Treat-
ment! Time! Kellgren, PZ 0.13; Treatment!Kellgren,
PZ 0.82. The average Treatment! Kellgren (95% CI)
D‘Pain on walking’ (in mm VAS, by group! Kellgren) was
HA[IeII]Z9 (17 to 0, PZ 0.055); HA[IIIeIV]Z1
(11 to 8, PZ 0.75); Corticosteroid[IeII]Z13 (21 to 5,
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Fig. 4. Values of (a) The Lequesne index and (b) The WOMAC
scores given as meanG SE.
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Fig. 5. Patient’s global assessments given as meanG SE.PZ 0.001); Corticosteroid[IIIeIV]Z8 (16 to 1,
PZ 0.069); Saline[IeII]Z3 (10 to 4, PZ 0.36); Sal-
ine[IIIeIV]Z1 (11 to 8, PZ 0.76).
There was no signiﬁcant interaction with the dichotomous
effusion in joint ([no]/[yes]) when the change (D) in ‘Pain
on walking’ was analyzed: Treatment! Time! Effusion,
PZ 0.26; Treatment! Effusion, PZ 0.15. The average
Treatment! Effusion (95% CI) D‘Pain on walking’ (in
mm VAS, by group!Effusion) was HA[no]Z11 (17
to 5, PZ 0.0003); HA[yes]Z 7 (9 to 22, PZ 0.40);
Corticosteroid[no]Z12 (18 to 5, PZ 0.0003); Cortico-
steroid[yes]Z15 (27 to 3, PZ 0.012); Sal-
ine[no]Z4 (10 to 2, PZ 0.22); Saline[yes]Z 0 (10
to 10, PZ 0.98). Subgroup analysis for patients below
and above the median age (66 years in our ITT-population)
did not reveal any signiﬁcant treatment differences (data not
presented).
Using the OARSI outcome measures33, at 14 days 53%
(95% CI: 36e70%) responded to HA, 56% (39e73%) to
corticosteroid, and 33% (18e49%) to placebo. At 28 days
the results were 53% (36e70%) response to HA, 66%
(49e82%) to corticosteroid, and 44% (28e61%) to placebo.
SAFETY
No hip-infections or other serious adverse events were
encountered during the study period. Thus, all patients
-25
-20
-15
-10
-5
0
5
10
0 14 28 90
0 14 28 90
HA [I-II]
HA [III-IV]
Saline [I-II]
Saline [III-IV]
Corticosteroid [I-II]
Corticosteroid [III-IV]
-30
-20
-10
0
10
20
30
HA[no]
HA[yes]
Saline[no]
Saline[yes]
Corticosteroid[no]
Corticosteroid[yes]
∆P
ai
n 
on
 w
al
ki
ng
 (m
m 
VA
S)
∆P
ai
n 
on
 w
al
ki
ng
 (m
m 
VA
S)
a
b
Fig. 6. Values are meanG SE for the change (D) in ‘Pain on walk-
ing’. (a) Dichotomized according to Kellgren grade ([IeII]/[IIIeIV]).
(b) Dichotomized according to effusion in joint ([no]/[yes]).
168 E. Qvistgaard et al.: Intra-articular treatment of hip osteoarthritiscould be treated throughout the study in the outpatients’
clinic and no admissions to the hospital were necessary.
The procedure, including both aspiration and injection of
the hip, was basically tolerated without problems except
for inevitable minor discomfort due to the sting of the nee-
dle. In some patients, the needling caused local pain and
had to be repeated a second time via another route of ac-
cess. One patient had a ﬂare of pain on the primary nee-
dling before any injection could be performed. However,
this patient was treated without problems the following
day. Three patients developed an adverse reaction with
a ﬂare of hip pain varying between hours to days after the
injection. In all these cases, the event passed without fur-
ther sequels. None of the patients who quit the study re-
ported pain on injection as a reason.
Discussion
The present study is, to our knowledge, the ﬁrst random-
ized, placebo-controlled trial of HA injections in the hip
joint. Numerous open-labeled, uncontrolled studies have in-
dicated an effect of HA in knee OA and the same effect has
been reported in hip OA20. In our study, the data handling
and analyses adhered strictly to the CONSORT statement28
and employed intention-to-treat statistics. As none of the in-
terventions studied has been properly evaluated before, it
was necessary to include a placebo group. The ES and
thereby the power of our study was chosen in the moderate
to high level with regard to the invasiveness and feasibility
of the intervention. If hip injections were to be included in
daily practice, the tediousness of the procedure as well as
the costs of medication etc. must be matched by a consider-
able beneﬁt. There was no statistically signiﬁcant effect of
HA on any outcome measure including the primary outcome
measure, i.e., ‘Pain on walking’, during the 3 months of in-
tervention. The group of patients treated with corticosteroids
experienced a signiﬁcant, but short lasting improvement
with an effect size indicating a moderate clinical effect
(ESZ 0.6). In none of the groups any tendency of effect
was observed at the 3-month follow-up. Our results are in
agreement with the general impression of joint injections
as a remedy in acute ﬂares of activity in both rheumatoid ar-
thritis43 and OA44. This a` priori assumption led us to search
for a high degree of acute effect and to limit the follow-up
time to 3 months. The present results conﬁrmed the notion
of an immediate rather than a long-lasting effect of injection,
whatever the substance used.
Although the effect following HA was not signiﬁcant, it can
be calculated that an ES of 0.4 (small to moderate clinical
effect) would require 100 patients per group to achieve sta-
tistical signiﬁcance with a power of 80%36; the actual power
in this trial in terms of HA vs saline was approximately 40%.
In comparison, using data from the meta-analysis by Lo
et al.10 and weighted for the number of patients analyzed,
we calculated the overall (arithmetic mean) ES of light-
weighted hyaluronan (Hyalgan) in knees to be 0.2310.
Whether HA of higher molecular weight might be of larger
value in hip joints remains to be studied. Subgroup analysis
was predestined in the protocol and the material dichoto-
mized according to the median age due to former indica-
tions of a positive effect for elderly patients in a similar
study of HA treatment of knee OA11. In our hip patients
no age-related treatment differences were observed. Earlier
experience from large open-labeled studies has suggested
a difference for HA on knee OA according to the degree of
radiographic changes, with a larger effect being observedon lightly affected knees45. Our results seemed to indicate
a similar tendency towards a relatively large effect of HA
on patients with lowish Kellgren gradings on hip radio-
grams. The size of our material only allowed a dichotomiza-
tion of the radiographic scores.
Given the possibility that corticosteroid might have
a more pronounced effect in patients with signs of inﬂam-
mation, e.g., joint effusion, a further subgroup analysis
based on presence or absence of effusion in the hip joint
at baseline was performed in our study. An effusion was
only present in 21 patients (Table I). However, HA had
a considerable effect on patients without effusion. In con-
trast, there was no effect from HA on patients with effusion.
Corticosteroid, on the other hand, had an effect on both pa-
tients with and without effusion. The effect of HA in patients
without effusion was comparable to the one observed fol-
lowing corticosteroids in the same subgroup of patients.
The intra-articular injections in the hip in all three treat-
ment groups were well tolerated by the OA patients and
easy to perform when guided by ultrasound. With this meth-
od, no radiation is given to the patient and the placement of
the needle can be veriﬁed before the injection is given27.
The experience with HA therapy in OA is based mostly on
data from studies of knee injections. Knee OA seems to re-
spond to these treatments to a varying degree46, although
there has been some indication of a publication bias and
a relative lack of negative studies in the literature10. The ef-
fect in knee OA seems to be obtained within 3 months cor-
responding to our observation period46. The number and
interval of HA injections could have inﬂuenced the effect.
The 14 days interval between HA injection was opted in re-
gard to patient security, as this period would be long
enough to diagnose a joint infection and differentiate this
from soft tissue irritation.
There was a deﬁnite, though short-lived effect of a cortico-
steroid injection and our results indicate that corticosteroids
may have some use in the treatment of hip OA in need of an
acute pain relief.
A similar course after corticosteroid injection of the knee
in OA has been indicated in earlier publications12. This has
led to the recommendation of corticosteroid therapy in se-
lected cases of knee OA, which is now, considering the re-
sults of the present RCT, evident for hip OA as well
(category 1b evidence47).
In accordance with observations in open-labeled studies
of corticosteroid injections in knee OA48, the presence of
effusion in the hip joint in our material seemed to be asso-
ciated with a good clinical response.
Although the effusion was aspirated in all groups, a recur-
rence of the effusion was observed in some of the patients.
However, in no cases did the amount of effusion exceed
more than a few milliliters.
It has previously been reported that the pain in hip OA
could be relieved by injection of large quantities of saline49.
A similar effect would not be expected with the use of
a mere 2 mL of saline, as in our study, and we regard the
saline-treated group as a proper placebo control. An effect
of saline has been reported in knee OA11. However, a la-
vage effect would not be expected with these small
quantities50.
In this study, numerous needle aspirations and injections
of the hip were given without serious adverse events and, in
general, this procedure may be regarded as innocuous and
safe16. At present, such injections should, however, be per-
formed without use of radiation26,27. Whether efﬁcient or
not, injection of HA seems to be safe when given with the
aid of ultrasound guidance51.
169Osteoarthritis and Cartilage Vol. 14, No. 2Costebeneﬁt analysis is only partly possible in relation to
the present study. With market prices in DK, three doses of
HA cost 24 times as much as one dose of methylpredniso-
lone (about $US263 vs $US11). To this should be added
the costs of extra consultations.
In agreement with the results in knee OA44 corticosteroid
seems to have a deﬁnite, albeit short-lived effect in hip OA,
regardless of subgrouping. It is not, however, expected that
any of the medications tested will have an effect of longer
duration or signiﬁcance at a clinically applicable level of ef-
fect size 33, 35. Based on the effect sizes calculated in the
present study, future controlled studies of hip injections with
these substances in parallel groups should include a mini-
mum of 100 patients in each group. In conclusion, this con-
trolled study could not demonstrate a 3-month effect on hip
OA using HA. Nevertheless, the treatment was quite harm-
less. Future studies should seek to clarify a possible impor-
tance of injections in subgroups of patients with hip OA.
Considering the costs and invasiveness of the procedures,
injections cannot be recommended as standard therapy in
hip OA for wider populations, and therefore the indications
remain a highly individualized matter.
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